Building clinically faithful ex vivo indolent lymphoma models for personalized therapy

项目摘要 由于它们的惰性性质，很少有细胞系或动物模型被建立用于慢性淋巴细胞性白血病。 白血病（CLL）和滤泡性淋巴瘤（FL）相比，其他类型的癌症。这个的主要目标 一个建议是建立一个离体惰性淋巴瘤（iNHL）模型，模拟体内肿瘤 微环境具有药物敏感性/耐药性的忠实读数，以实现个性化医疗。的 中心假设是具有肿瘤微环境（TME）模拟的离体模型将使iNHL 表现出生理学上的行为，并为药物测试提供临床上的可靠模型。根据我们的初步数据， 本研究的目的是通过以下两个具体目标来实现：1）完善和建立离体iNHL模型 将最好地支持肿瘤细胞在体内的行为; 2）通过将模型化的 药物反应与患者的临床反应和/或突变谱。在第一个目标中，优化的离体 iNHL模型将通过用B细胞生长因子转导骨髓成纤维细胞（BMF）来产生， 模仿在淋巴结中的肿瘤环境中发现的不同细胞类型。后续共培养诱导 将测量细胞行为的变化，包括细胞增殖和粘附，这是罕见的。 在不存在合适的iNHL模型的情况下测量。然后，我们的目标是证明该模型是临床上 相关的和潜在的有用的。我们将把个体模型细胞反应与临床反应相关联 使用每个患者的肿瘤细胞为60名患者构建个性化治疗方案， 模型我们相信这项研究是创新的，因为一个实用的和临床上忠实的个性化 目前不存在惰性淋巴瘤的Rx模型。预计最终的模型将是 快速、简单、经济，为个体患者提供个性化的药物试验。通过这个模型，我们寻求 为了iNHL的利益，向在临床上实施个性化医疗的现实迈进 患者成功完成拟议的研究将带来以下切实的好处：1）模型 其概括了能够评价难治性惰性淋巴瘤的体内行为的iNHL-TME， 由于缺乏合适的模型，目前无法实现; 2）实用（快速、简单和经济）， 临床上可靠的模型，可用于指导临床中的个体化治疗选择， 直接的患者受益; 3）大量的遗传异质性肿瘤模型，这将简化 未来药物开发的效率;以及4）建模方法可能适用于其他惰性药物， 以及侵袭性淋巴瘤。

Project Summary Due to their indolent nature, few cell lines or animal models have been established for chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL) compared to other types of cancer. The primary goal of this proposal is to establish an ex vivo indolent lymphoma (iNHL) model that mimics the tumor in vivo microenvironment with faithful readouts of drug sensitivity/ resistance to enable personalized medicine. The central hypothesis is that an ex vivo model with tumor microenvironment (TME) mimicry would make iNHL behave physiologically and provide a clinical faithful model for drug testing. Guided by our preliminary data, the objective will be achieved by the following two specific aims: 1) To refine and build ex vivo iNHL models that will best support tumor cell in vivo behaviors; 2) To validate the models by correlating modeled drug response with patients’ clinical response and/or mutation profiles. In the first aim, optimized ex vivo iNHL models will be created by transducing bone marrow fibroblasts (BMF) with B-cell growth factors, mimicking different cell types found in the tumor milieu in the lymph nodes. Subsequent co-culture-induced changes in cellular behaviors will be measured including cell proliferation and adhesion that are rarely measured in the absence of suitable iNHL models. We then aim to demonstrate that the model is clinically relevant and potentially useful. We will correlate individual modeled cellular response with the clinical response and/or mutation profiles for 60 patients using each patient’s tumor cells to build a personalized therapeutic model. We believe the proposed study is innovative because a practical and clinically faithful personalized Rx model is currently non-existent for indolent lymphoma. It is anticipated that the eventual model will be fast, simple, and economical, enabling a personalized drug trial for individual patients. With the model, we seek to make a stride towards the reality of practicing personalized medicine in the clinic for the benefits of iNHL patients. Successful completion of the proposed research will deliver the following tangible benefits: 1) Models which recapitulate the iNHL-TME that enable evaluation of in vivo behaviors of refractory indolent lymphoma, not currently achievable with the lack of suitable models; 2) Practical (fast, simple, and economical) and clinically faithful models which may be used to guide individualized therapy selection in the clinic leading to direct patient benefits; 3) A large number of genetically heterogeneous tumor models which will streamline the efficiency of future drug development; and 4) A modeling approach potential applicable to other indolent as well as aggressive lymphomas.